Jaguar LAA, Inc., a privately held medical device company, announced on Sept. 11, 2026 that it acquired assets related to the Laminar program from Johnson & Johnson, according to PR Newswire. The Laminar program is focused on addressing the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation (AFib), and the announcement said the transaction positions Jaguar to advance the program and its approach to LAA closure, according to PR Newswire. Financial terms of the transaction were not disclosed.
What Jaguar acquired and how the company is structured
The transaction brings key Laminar program assets together with members of the team responsible for their development in a newly formed, independent company, according to PR Newswire. Jaguar said it intends to build on the clinical and development work completed to date and advance the Laminar program through its next stages of development and regulatory review.
Jaguar was formed in partnership with Santé Ventures and members of the Laminar management team. Santé, alongside management and other investors, led the formation and financing of Jaguar and the transaction with Johnson & Johnson.
Laminar program focus and clinical rationale described in the release
AFib is described as a common heart rhythm disorder associated with an increased risk of stroke, according to PR Newswire. In patients with non-valvular AFib, the LAA is described as an important source of thrombus formation and an area of clinical focus in cardiology and electrophysiology.
The Laminar program uses a catheter-based approach and rotational motion to close and eliminate the LAA while leaving minimal device exposure within the left atrium. Jason Rogers, chief medical officer of Jaguar, said Jaguar believes the Laminar technology offers a differentiated approach to LAA closure, “particularly through its ability to leave minimal device exposure within the left atrium.”
Rogers added that Jaguar is “excited to continue the work behind the program and explore its potential to provide an important new treatment option for patients with atrial fibrillation,” according to the release.
Company and investor details included in the announcement
Jaguar LAA, Inc. said it is focused on developing catheter-based technologies for left atrial appendage closure intended to reduce the risk of stroke in patients with non-valvular atrial fibrillation. Jaguar said it is headquartered in Santa Rosa, California.
Santé Ventures is described as a healthcare and life sciences investment firm founded in 2006 with more than $1 billion in capital under management, according to PR Newswire. The firm said it invests in early-stage medical technologies, biotechnology, and digitally enabled healthcare services, and it has offices in Austin, Texas, and Boston, Massachusetts.
Widely known context: PR Newswire is a press release distribution service used by companies and investors to publish corporate announcements. Widely known context: Johnson & Johnson is a global healthcare company.
